Amerikas Savienotās Valstis - angļu - NLM (National Library of Medicine)

carilion materials management - naproxen (unii: 57y76r9atq) (naproxen - unii:57y76r9atq) - naproxen 500 mg - carefully consider the potential benefits and risks of naproxen delayed-release tablets and other treatment options before deciding to use naproxen delayed-release tablets. use the lowest effective dosage for the shortest duration consistent with individual patient treatment goals (see warnings: gastrointestinal bleeding, ulceration, and perforation ). naproxen delayed-release tablets are indicated: naproxen as naproxen suspension is recommended for juvenile rheumatoid arthritis in order to obtain the maximum dosage flexibility based on the patient’s weight. naproxen delayed-release tablets are not recommended for initial treatment of acute pain because the absorption of naproxen is delayed compared to absorption from other naproxen-containing products (see clinical pharmacology, dosage and administration ). naproxen delayed-release tablets are contraindicated in the following patients:

Amerikas Savienotās Valstis - angļu - NLM (National Library of Medicine)

physicians total care, inc. - naproxen (unii: 57y76r9atq) (naproxen - unii:57y76r9atq) - naproxen 500 mg - carefully consider the potential benefits and risks of naproxen delayed-release tablets and other treatment options before deciding to use naproxen delayed-release tablets. use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see warnings ). naproxen delayed-release tablets are indicated: - for the relief of the signs and symptoms of rheumatoid arthritis - for the relief of the signs and symptoms of osteoarthritis - for the relief of the signs and symptoms of ankylosing spondylitis - for the relief of the signs and symptoms of juvenile arthritis naproxen delayed-release tablets are not recommended for initial treatment of acute pain because the absorption of naproxen is delayed compared to absorption from other naproxen-containing products (see clinical pharmacology and dosage and administration ). all naproxen products are contraindicated in patients with known hypersensitivity to naproxen. all naproxen products should not be given to patients w

Malta - angļu - Medicines Authority

sandoz pharmaceuticals d.d. verovškova ulica 57, si-1000 ljubljana, slovenia - nevirapine - tablet - nevirapine 200 mg - antivirals for systemic use

Lielbritānija - angļu - MHRA (Medicines & Healthcare Products Regulatory Agency)

milpharm ltd - nevirapine - tablet - 200mg

Japāna - angļu - すりの適正使用協議会 RAD-AR Council, Japan

eisai co., ltd. - aspirin; dihydroxyaluminum aminoacetate; magnesium carbonate - light orange tablet, diameter 8.0 mm, thickness 3.8 mm

Ēģipte - angļu - EDA (Egyptian Drug Authority)

novartis consumer health-switzerland - tablet - 325 mg

Kanāda - angļu - Health Canada

mcneil consumer healthcare division of johnson & johnson inc - acetaminophen - tablet - 325mg - acetaminophen 325mg - miscellaneous analgesics and antipyretics

Kanāda - angļu - Health Canada

mcneil consumer healthcare division of johnson & johnson inc - acetaminophen - tablet - 325mg - acetaminophen 325mg - miscellaneous analgesics and antipyretics

Kanāda - angļu - Health Canada

mcneil consumer healthcare division of johnson & johnson inc - acetaminophen - tablet (chewable) - 160mg - acetaminophen 160mg - miscellaneous analgesics and antipyretics